• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Investigations on the pharmacokinetics of propafenone in man.

作者信息

Hollmann M, Brode E, Hotz D, Kaumeier S, Kehrhahn O H

出版信息

Arzneimittelforschung. 1983;33(5):763-70.

PMID:6683556
Abstract

The pharmacokinetics of propafenone (Rytmonorm) was studied in 19 healthy volunteers. Propafenone was given intravenously (commercial ampoules of 70 mg) and orally in different doses (150, 300, 450 mg) and forms (solution, commercial film tablets). The results show a dose dependence of bioavailability and maximum plasma concentrations after oral application with over-proportionate increase at higher dose levels yielding bioavailabilities up to 40-50% with single applications of 450 mg. This is interpreted as saturability of a presystemic mechanism during invasion (most probably of the metabolizing enzyme systems of the liver). The mean rate constant of elimination after intravenous application is beta = 0.28 h-1 (95% confidence limits: 0.24-0.33 h-1) corresponding to a half-life of 2.5 h. There are no significant differences in these values after oral application and different dosages. The total plasma clearance of 1.0 1/min (95% confidence limits: 0.9-1.1 1/min) is almost exclusively metabolic. After 12 days of oral dosing (2 tablets of 150 mg propafenone daily) no statistically significant changes of kinetic parameters could be demonstrated although with some volunteers the total clearance decreased. It is considered that in some persons with relatively low clearance the plasma concentrations may reach levels at which a saturation of enzymatic reactions of metabolism may become relevant even after application of such low single doses as 150 mg.

摘要

相似文献

1
Investigations on the pharmacokinetics of propafenone in man.
Arzneimittelforschung. 1983;33(5):763-70.
2
[Clinical pharmacology of propafenone].
G Ital Cardiol. 1984 Apr;14(4):285-92.
3
[Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers].普罗帕酮对口服地高辛药代动力学的影响:一项在健康志愿者中的研究
G Ital Cardiol. 1986 Mar;16(3):237-40.
4
Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.利福平治疗对CYP2D6快代谢型和慢代谢型患者中普罗帕酮处置的影响。
Pharmacogenetics. 1999 Oct;9(5):551-9.
5
Bioavailability of an extemporaneous suspension of propafenone made from tablets.由片剂制成的普罗帕酮临时混悬液的生物利用度。
Biopharm Drug Dispos. 2006 Jul;27(5):241-5. doi: 10.1002/bdd.505.
6
The pharmacokinetics, bioequivalence and bioavailability of different formulations of metoclopramide in man.甲氧氯普胺不同制剂在人体中的药代动力学、生物等效性和生物利用度。
Arzneimittelforschung. 1981;31(6):1041-5.
7
Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.催产素受体拮抗剂L-368,899在大鼠和犬体内的药代动力学及处置情况。
Drug Metab Dispos. 1997 Oct;25(10):1113-8.
8
Propafenone disposition kinetics in cardiac arrhythmia.
Clin Pharmacol Ther. 1984 Aug;36(2):163-8. doi: 10.1038/clpt.1984.157.
9
Methotrexate: bioavailability and pharmacokinetics.甲氨蝶呤:生物利用度与药代动力学
Cancer Treat Rep. 1985 Jul-Aug;69(7-8):833-8.
10
Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations.
Am J Cardiol. 1984 Nov 14;54(9):9D-12D. doi: 10.1016/s0002-9149(84)80278-7.

引用本文的文献

1
Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease.伴有或不伴有先天性心脏病的年轻患者应用 Ic 类抗心律失常药物进行医学电复律转复心房颤动和房扑。
J Cardiovasc Electrophysiol. 2023 Dec;34(12):2545-2551. doi: 10.1111/jce.16095. Epub 2023 Oct 17.
2
Microdosing and drug development: past, present and future.微量给药与药物研发:过去、现在与未来。
Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):817-34. doi: 10.1517/17425255.2013.786042. Epub 2013 Apr 4.
3
Therapeutic drug monitoring of antiarrhythmic drugs.
抗心律失常药物的治疗药物监测
Clin Pharmacokinet. 2003;42(7):647-63. doi: 10.2165/00003088-200342070-00004.
4
Dissolution and in vivo evidence of differences in reference products: impact on development of generic drugs.参比制剂的溶出度及体内差异证据:对仿制药开发的影响
Eur J Drug Metab Pharmacokinet. 2000 Jan-Mar;25(1):18-24. doi: 10.1007/BF03190051.
5
Individual variation in first-pass metabolism.首过代谢的个体差异。
Clin Pharmacokinet. 1993 Oct;25(4):300-28. doi: 10.2165/00003088-199325040-00005.
6
Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.普罗帕酮治疗心律失常。风险效益评估。
Drug Saf. 1995 Jan;12(1):55-72. doi: 10.2165/00002018-199512010-00005.
7
Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.普罗帕酮。对其药理学、药代动力学及在心律失常治疗中的应用的重新评估。
Drugs. 1993 Jan;45(1):85-130. doi: 10.2165/00003495-199345010-00008.
8
Beta-blocking and electrophysiological effects of propafenone in volunteers.
Eur J Clin Pharmacol. 1983;25(6):831-3. doi: 10.1007/BF00542530.
9
Clinical pharmacokinetics of the newer antiarrhythmic agents.新型抗心律失常药物的临床药代动力学
Clin Pharmacokinet. 1984 Sep-Oct;9(5):375-403. doi: 10.2165/00003088-198409050-00001.
10
Drug interaction between propafenone and metoprolol.普罗帕酮与美托洛尔之间的药物相互作用。
Br J Clin Pharmacol. 1987 Aug;24(2):213-20. doi: 10.1111/j.1365-2125.1987.tb03164.x.